Abiraterone approved for clinical use in Scotland

As previously projected, the Scottish Medicines Consortium has now approved the clinical use of abiraterone acetate, making the drug available for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after failure of treatment with docetaxel-based chemotherapy throughout the United Kingdom.

Tea drinking and risk for prostate cancer (in Scotland if nowhere else)

Back in the dim and distant past (i.e., the 1960s and 1970s), relatively high levels of tea consumption were common in most of the United Kingdom, and coffee was an uncommon substitute. This is certainly not so true today. However, … READ MORE …